Category: Bio/Pharma/CRO
Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows Thermo Fisher and the Biopharmaceutical Analysis Training Laboratory (BATL) of Northeastern University aim to deliver cutting-edge analytical solutions and training programs SAN JOSE, Calif., Nov. 4, 2020 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and the Biopharmaceutical... Read more
Thermo Fisher Scientific Extends Collaboration to Advance Biopharmaceutical Discovery and Development
Thermo Fisher and Symphogen continue work to support the development of innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows Read more
Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings Oral,... Read more
Roche announces full FDA approval for Venclexta combinations for acute myeloid leukaemia
Approval supported by data from phase III confirmatory trials, VIALE-A and VIALE-C VIALE-A study showed Venclexta plus azacitidine significantly improved overall survival in newly diagnosed AML compared to azacitidine alone Supplemental New Drug Applications approved under the FDA’s Real-Time Oncology Review pilot programme and Project Orbis initiative Basel, 19 October 2020 – Roche (SIX: RO,... Read more
Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance to Deliver Integrated hiPSC Drug Discovery Solutions
MILAN (Italy) and MADISON (Wis., USA) – October 6, 2020 – Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process.... Read more
PerkinElmer Signals Notebook and PerkinElmer Signals Medical Review Cloud-Based Software Gain SOC 2 Attestation for Biopharmaceutical Research and Clinical Trial Data
Company’s Informatics Solutions Meet AICPA’s Trust Service Principles for Security, Confidentiality & Availability WALTHAM, Mass. – September 30, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the PerkinElmer Signals™ Notebook and PerkinElmer Signals™ Medical Review SaaS solutions have been granted SOC 2 Level 1 Attestation for... Read more
Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy Final overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours... Read more
Roche’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
EMPACTA is the first global phase III trial to show efficacy with Actemra/RoActemra in COVID-19 associated pneumonia and the first with a focus on enrolling largely underserved and minority patients There was no statistical difference in mortality between patients who received Actemra/RoActemra or placebo Roche plans to share these results with health authorities, including the... Read more
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer
Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs More... Read more